Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
20 independent labs in 15 countries
2 findings against
160 trials, 17 about aging, 40 with no results posted
Journal of cachexia, sarcopenia and muscle, Jun 18, 2024
What did studies of testosterone undecanoate find?
66
Studies of testosterone undecanoate measured 66 outcomes; the most studied are body weight (6 studies), HbA1c (3) and sexual function (2).
Body weight
↓downin humans5↔no changein humans1
6 studies
Testosterone undecanoate decreases body weight in humans (added to tirzepatide in late responders, compared with tirzepatide monotherapy) (significantly greater reduction than group A).
“At 6 months, group B demonstrated significantly greater body weight and fat mass reduction compared to group A (P<0.05).”
Human trialadded to tirzepatide in late responders, compared with tirzepatide monotherapy1000 mg intramuscular6 monthsmalesn = 5
Testosterone undecanoate showed no clear effect on body weight in humans following VLED and at study end (-11.4 kg vs -10.9 kg, P=0.80).
“Cases and controls lost the same weight after VLED (testosterone -12.0 kg; placebo -13.5 kg, P=0.40) and maintained this at study end (testosterone -11.4 kg; placebo -10.9 kg, P=0.80).”
Human trialfollowing VLED and at study endintramuscular56 weeksmalesn = 100
Testosterone undecanoate decreases body weight in humans (hypogonadal men).
“Obese men and men with the largest waist circumference showed the strongest declines over 2 years in weight, waist circumference and body mass index (BMI)”
Human trialhypogonadal menparenteral2 yearsmalesn = 110
Testosterone undecanoate decreases body weight in humans (type 2 diabetes, visceral obesity and androgen deficiency) (-2.66% body weight, -3.96% waist-hip ratio, -5.65% body fat).
“TU had a positive effect on (visceral) obesity: statistically significant reduction in body weight (2.66%), waist-hip ratio (-3.96%) and body fat (-5.65%)”
Human trialtype 2 diabetes, visceral obesity and androgen deficiencyoral120 mg daily3 monthsmalesn = 24
Testosterone undecanoate improves sexual function in humans (added to tirzepatide in late responders, compared with tirzepatide monotherapy) (IIEF-5 23.2±2.1 vs. 18.0±1.5).
“sexual health (IIEF-5: 23.2±2.1 vs. 18.0±1.5, P<0.001)”
Human trialadded to tirzepatide in late responders, compared with tirzepatide monotherapy1000 mg intramuscular6 monthsmalesn = 5
Testosterone undecanoate improves insulin sensitivity in humans (added to tirzepatide in late responders, compared with tirzepatide monotherapy) (HOMA-IR 2.9±0.6 vs. 3.8±0.7).
“superior improvements in insulin sensitivity (HOMA-IR: 2.9±0.6 vs. 3.8±0.7, P<0.01)”
Human trialadded to tirzepatide in late responders, compared with tirzepatide monotherapy1000 mg intramuscular6 monthsmalesn = 5
Testosterone undecanoate improves insulin sensitivity in humans (obese men with severe OSA on a hypocaloric diet) (-1.14 units, 95% CI -2.27 to -0.01, P<0.05).
Testosterone undecanoate increases lean body mass in humans (66.1±3.1 kg vs. 63.4±3.0 kg in group A).
“group B achieved significant LBM recovery (66.1±3.1 kg vs. 63.4±3.0 kg in group A, P<0.01).”
Human trialadded to tirzepatide in late responders, compared with tirzepatide monotherapy, where group A lost lean mass1000 mg intramuscular6 monthsmalesn = 5
Testosterone undecanoate showed no clear effect on C-reactive protein in humans (low testosterone levels (<13.7 nmol/L)) (median hs-CRP 2.20 vs 2.00 mg/L, P = .36).
“After 26 weeks of testosterone supplementation therapy, the 2 intervention groups were not statistically significantly different (median hs-CRP 2.20 vs 2.00 mg/L, interquartile range 0.40-6.54 vs 0.50-5.70, P = .36).”
“In the TRT group, there was a significant decrease in sperm concentration (relative change −0.67 (−88; −54), p = 0.028) and total number (relative change −0.59 (−87; 50), p = 0.018).”
Testosterone undecanoate decreases frailty in humans (cirrhosis with sarcopenia receiving nutrition and exercise) (p = 0.01).
“Liver frailty index improved significantly in the NExT group compared with the NEx group at 24 weeks (3.98 ± 0.27 to 3.32 ± 0.21 vs. 3.93 ± 0.24 to 3.68 ± 0.22, respectively; p = 0.01).”
Human trialcirrhosis with sarcopenia receiving nutrition and exerciseintramuscular injection1000 mg24 weeksmalesn = 102
Testosterone undecanoate increases appendicular skeletal muscle index in humans (cirrhosis with sarcopenia receiving nutrition and exercise) (64.1% vs 25.3%, p < 0.001).
“a ≥ 10% increase in ASMI was achieved in 41/64 (64.1%) patients in the NExT group compared with 16/63 (25.3%) in the NEx group (p < 0.001).”
Human trialcirrhosis with sarcopenia receiving nutrition and exerciseintramuscular injection1000 mg24 weeksmalesn = 127
Testosterone undecanoate lowers the risk of type 2 diabetes in humans (impaired glucose tolerance or newly diagnosed type 2 diabetes) (adjusted OR 0.48 (95% CI: .30-.76)).
“which became 0.48 (95% CI:.30-.76) after adjustment for covariates.”
Human trialimpaired glucose tolerance or newly diagnosed type 2 diabetesinjections1000 mg every 3 months2 yearsmalesn = 709
Testosterone undecanoate is associated with blood pressure in humans (adult-onset testosterone deficiency) (Without antihypertensive agents: median systolic BP change −12.5 mmHg, diastolic BP change −8.0 mmHg, and pulse pressure change −6.0 mmHg).
“TU was associated with significant reductions in systolic, diastolic BP and pulse pressure, regardless of antihypertensive therapy”
Testosterone undecanoate is associated with serum metabolites in humans.
“cystine, lysine and tyrosine were shown to change in correlation with insulin sensitivity and high-density lipoprotein cholesterol levels in response to testosterone”
Human trialserum40 mg every second day3 monthsfemales
Having reached the sample size described for the interim analysis and having seen the post-interim results, the sponsor has decided to stop the trial due to futility.
At 24 weeks, an arm-and-leg muscle mass index rose at least 10% in 64.1% given added testosterone, versus 25.3% with nutrition and exercise alone.At 24 weeks, an arm-and-leg muscle mass index rose at least 10% in 64.1% given added testosterone, versus 25.3% with nutrition and exercise alone.